Immuneering Announces Positive Initial Phase 1 Pharmacokinet

Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities or... | April 18, 2023

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , San Diego , California , American , Gina Nugent , Kiki Patel , Laurence Watts , Ben Zeskind , Brett Hall , Scott Barrett , Immuneering Corporation Nasdaq , Immuneering Corporation , American Association For Cancer Research , Nugent Communications , Exchange Commission , Gilmartin Group , American Association , Cancer Research , Chief Executive Officer , Chief Scientific Officer , Chief Medical Officer , Immuneering Corporation Stock Exchange , News , Information , Press Release , Data , Resented , It , Racr , Nnual , Meeting , Support , Potential , O , Address , Road , Population , F , Patients , Ith , Gas , Mutant , Fell , Ctolerated , Nose , Relimiting , Oxicities Imrx Us45254e1073 ,